Investigating the Association Between Serum Pro- and Anti-Inflammatory Cytokines Concentration and in-stent Sestenosis: A Case Control Study

Document Type : Original Article


1 International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.

2 National Center Fir Health Insurance Research, Tehran, Iran.

3 Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.

4 Department of Cardiology, Chamran Hospital, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

5 Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.

6 Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

7 Department of Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

8 Cardiologist, Interventionist Fellowship, Shiraz University of Medical Sciences, Shiraz, Iran.

9 Department of Biostatistics and Epidemiology, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.

10 Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

11 Department of Genetics, Faculty of Medicine and Genetics Laboratory AL Zahra Hospital, Isfahan University of Medicine, Isfahan, Iran.

12 Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.

13 Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

14 Division of Applied Medicine, Medical School, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK.

15 Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.


Introduction : It has been shown that angioplasty and endovascular stent deployment, used after coronary revascularization, are associated with an inflammatory response. Inflammation has a key role in the complications of atherosclerotic plaque, coronary artery disease (CAD) and in-stent restenosis (ISR). The objectives of the present study was to investigate serum levels of 12 pro/anti-cytokines and growth factors and their relationship with restenosis.
Methods: A total of 244 subjects were recruited in current study including unrelated patients who previously underwent coronary stent implantation (between 2014 and 2017) and were subsequently indicated for coronary angiography. According to angiography results patients were allocated into two groups: cases with stenosis more than 50% within the stent (N=79) and controls with stenosis less than 50% within the stent (N=165). Serum was separated by centrifuging the blood for 15 min at 1000 rpm.  Serum cytokines levels including IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, IFN-γ, MCP-1, EGF, and VEGF were measured using an EV 3513 cytokine biochip array (Randox Laboratories, Crumlin, UK).
Results: The mean age of the NISR and ISR groups were 62.47±9.2 and 59.49±8.48 years, respectively. The diabetes frequency was significantly higher in the ISR group (55.1%) compared with NISR group (30.9%) (p<0.001). There was no significant difference in levels of cytokines between the two groups (p>0.05).
Conclusions: The results showed that serum levels of pro/anti-inflammatory cytokines and growth factors did not have a significant difference between NISR and ISR study groups.


  1. Van der Kooy K, Van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. International Journal of Geriatric Psychiatry: A journal of the psychiatry of late life and allied sciences. 2007 Jul;22(7):613-26.
  2. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. Journal of the American College of Cardiology. 2002 Jan 16;39(2):183-93.
  3. Simon DI. Inflammation and vascular injury. Circulation Journal. 2012;76(8):1811-8.
  4. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arteriosclerosis, thrombosis, and vascular biology. 2002 Nov 1;22(11):1769-76.
  5. Jukema JW, Verschuren JJ, Ahmed TA, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nature Reviews Cardiology. 2012 Jan;9(1):53-62.
  6. Min X, Lu M, Tu S, Wang X, Zhou C, Wang S, et al. Serum cytokine profile in relation to the severity of coronary artery disease. BioMed research international. 2017;2017.
  7. Tashiro H, Shimokawa H, Sadamatsu K, Aoki T, Yamamoto K. Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coronary artery disease. 2001 Mar 1;12(2):107-13.
  8. Gotsman I, Stabholz A, Planer D, Pugatsch T, Lapidus L, Novikov Y, et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden?. The Israel medical association journal. 2008 Jul 1;10(7):494.
  9. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart. 2000 Jul 1;84(1):83-7.
  10. Jordan NJ, Watson ML, Williams RJ, Roach AG, Yoshimura T, Westwick J. Chemokine production by human vascular smooth muscle cells: modulation by IL‐13. British journal of pharmacology. 1997 Oct;122(4):749-57.
  11. Rader DJ. Inflammatory markers of coronary risk. New England Journal of Medicine. 2000 Oct 19;343(16):1179-82.
  12. Soflaei SS, Saberi-Karimian M, Baktashian M, Tajfard M, Alimi H, Tayefi M, et al. Investigating the inflammatory status in the patients candidate for second angiography after coronary stent implantation. Acta Cardiologica. 2023 Jan 2;78(1):80-5.
  13. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. The lancet oncology. 2013 May 1;14(6):e218-28.
  14. Spelman K, Burns JJ, Nichols D, Winters N, Ottersberg S, Tenborg M. Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. Alternative medicine review. 2006 Jun 1;11(2):128.
  15. Sueishi K, Yonemitsu Y, Nakagawa K, Kaneda Y, Kumamoto M, Nakashima Y. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. ATHEROSCLEROSIS IV: RECENT ADVANCES IN ATHEROSCLEROSIS RESEARCH. 1997 Jan 1;811:311-24.
  16. Chalikias GK, Tziakas DN, Kaski JC, Hatzinikolaou EI, Stakos DA, Tentes IK, et al. Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis. 2005 Sep 1;182(1):135-43.
  17. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheterization and Cardiovascular Interventions. 2013 Oct 1;82(4):E266-355.
  18. Mirhafez SR, Pasdar A, Avan A, Esmaily H, Moezzi A, Mohebati M, et al. Cytokine and growth factor profiling in patients with the metabolic syndrome. British journal of nutrition. 2015 Jun;113(12):1911-9.
  19. Vučević D, Radak Đ, Radosavljević T, Mladenović D, Milovanović I. Inflammatory process in atherogenesis: new facts about old flame. Medicinski pregled. 2012;65(9-10):388-95.
  20. Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis—effects of lipid-lowering therapy. Journal of atherosclerosis and thrombosis. 2011;18(5):351-8.
  21. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arteriosclerosis, thrombosis, and vascular biology. 2008 Nov 1;28(11):1897-908.
  22. Baktashian M, Soflaei SS, Kosari N, Salehi M, Khosravi A, Ahmadinejad M, et al. Association of high level of hs-CRP with in-stent restenosis: a case-control study. Cardiovascular Revascularization Medicine. 2019 Jul 1;20(7):583-7.
  23. Mirhafez SR, Zarifian A, Ebrahimi M, Ali RF, Avan A, Tajfard M, et al. Relationship between serum cytokine and growth factor concentrations and coronary artery disease. Clinical biochemistry. 2015 Jun 1;48(9):575-80.
  24. Sukhija R, Fahdi I, Garza L, Fink L, Scott M, Aude W, et al. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. The American journal of cardiology. 2007 Apr 1;99(7):879-84.
  25. Zhou RH, Shi Q, Gao HQ, Shen BJ. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. Journal of atherosclerosis and thrombosis. 2001;8(1):30-2.
  26. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. The FASEB Journal. 1992 May;6(8):2591-9.
  27. Sica A, Matsushima K, Van Damme J, Wang JM, Polentarutti N, Dejana E, et al. IL-1 transcriptionally activates the neutrophil chemotactic factor/IL-8 gene in endothelial cells. Immunology. 1990 Apr;69(4):548.
  28. Molad YA, Haines KA, Anderson DC, Buyon JP, Cronstein BN. Immunocomplexes stimulate different signalling events to chemoattractants in the neutrophil and regulate L-selectin and beta 2-integrin expression differently. Biochemical Journal. 1994 May 5;299(Pt 3):881.
  29. Simonini A, Moscucci M, Muller DW, Bates ER, Pagani FD, Burdick MD, et al. IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation. 2000 Apr 4;101(13):1519-26.
  30. Goldberg A, Zinder O, Zdorovyak A, Diamond E, Lischinsky S, Gruberg L, et al. Diagnostic coronary angiography induces a systemic inflammatory response in patients with stable angina. American heart journal. 2003 Nov 1;146(5):819-23.
  31. Egan CG, Caporali F, Huqi AF, Zito MC, Focardi M, Mondillo S, et al. Reduced levels of putative endothelial progenitor and CXCR4+ cells in coronary artery disease: kinetics following percutaneous coronary intervention and association with clinical characteristics. Thrombosis and haemostasis. 2009;101(06):1138-46.
  32. Stiefel P, Moreno-Luna R, Vallejo-Vaz AJ, Beltran LM, Costa A, Gomez L, et al. Which parameter is better to define endothelial dysfunction in a test of postocclusive hyperemia measured by laser-Doppler flowmetry?. Coronary artery disease. 2012 Jan 1;23(1):57-61.
  33. Taggart DP. Coronary-artery stents. The New England journal of medicine. 2006 May 1;354(19):2076-8.
  34. Marfella R, Sasso FC, Siniscalchi M, Paolisso P, Rizzo MR, Ferraro F, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention is associated with a lower rate of in-stent restenosis in patients with acute ST-elevation myocardial infarction. The Journal of Clinical Endocrinology & Metabolism. 2012 Aug 1;97(8):2862-71.
  35. Chan JM, Rhee JW, Drum CL, Bronson RT, Golomb G, Langer R, et al. In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid–polymeric nanoparticles. Proceedings of the National Academy of Sciences. 2011 Nov 29;108(48):19347-52.
  36. Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circulation: Cardiovascular Interventions. 2011 Feb;4(1):104-11.
  37. Liang S, Aiqun M, Jiwu L, Ping Z. TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients. Immunologic research. 2016 Apr;64:424-30.
  38. Yan KP, Guo Y, Xing Z, Huang X, Dai S, Duan M, et al. Dan-Shen-Yin protects the heart against inflammation and oxidative stress induced by acute ischemic myocardial injury in rats. Experimental and Therapeutic Medicine. 2012 Feb 1;3(2):314-8.
  39. Hojo Y, Ikeda U, Katsuki TA, Mizuno O, Fukazawa H, Fujikawa H, et al. Chemokine expression in coronary circulation after coronary angioplasty as a prognostic factor for restenosis. Atherosclerosis. 2001 May 1;156(1):165-70.
  40. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arteriosclerosis, thrombosis, and vascular biology. 2001 Mar;21(3):327-34.
  41. 41.  Boldt A, Garbade J, Wetzel U, Hindricks G, Kottkamp H, Gummert J, et al. Progressive angiogenesis and lone atrial fibrillation: The expression of VEGF, bFGF and AT2 in the fibrillating human atrium. The Thoracic and Cardiovascular Surgeon. 2004;52(S 1):PP_29.